Previous close | 2.4300 |
Open | 2.4400 |
Bid | 2.4100 x 100 |
Ask | 2.4600 x 100 |
Day's range | 2.4350 - 2.4860 |
52-week range | 2.3600 - 4.3000 |
Volume | |
Avg. volume | 429,565 |
Market cap | 241.476M |
Beta (5Y monthly) | 1.45 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.1500 |
Earnings date | 24 Apr 2024 - 29 Apr 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 8.75 |
Accuray (ARAY) announces the latest data that supports the use of its CyberKnife System in the treatment of recurrent prostate cancer with stereotactic body radiation therapy.
Accuray Incorporated (NASDAQ: ARAY) announced today that new data presented at the 2024 Radiosurgery Society Meeting in Chicago, Illinois support the use of the CyberKnife® System in the treatment of high-risk and recurrent prostate cancer. The studies expand on years of published clinical follow-up with a large number of prostate cancer patients with various stages of disease, as well as with those who were previously treated with radiotherapy – supporting the system's versatility and value to
Accuray's (ARAY) solid product demand raises optimism about the stock.